Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - oxcarbazepine, quantity: 60 mg/ml - oral liquid, suspension - excipient ingredients: saccharin sodium; propylene glycol; purified water; methyl hydroxybenzoate; sorbitol solution (70 per cent) (non-crystallising); peg-8 stearate; sorbic acid; propyl hydroxybenzoate; ascorbic acid; dispersible cellulose; fragrance (perfume) - for use as monotherapy or adjunctive therapy for the treatment of partial seizures and generalised tonic-clonic seizures, in adults and children.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 60 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression sclerotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 40 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression sclerotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 20 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression. sclerotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 10 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression sclerotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 4000 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Kenya - Kiingereza - Pharmacy and Poisons Board

macrogol, sodium chloride, sodium bicarbonate,… - powder for oral solution - macrogol 3350 13.125g sodium chloride 350.7mg… - macrogol combinations

Japani - Kiingereza - すりの適正使用協議会 RAD-AR Council, Japan

maruishi pharmaceutical. co., ltd. - macrogol ointment - white ointment

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

dendy pharmaceuticals pty ltd - macrogol 3350, quantity: 1 g/g - solution, powder for - excipient ingredients: - decrease/reduce/relieve constipation ; aperient/laxative ; helps reduce occurrence of constipation

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - macrogol 3350, quantity: 13125 mg; potassium chloride, quantity: 46.6 mg; sodium chloride, quantity: 350.7 mg; sodium bicarbonate, quantity: 178.5 mg - powder, oral - excipient ingredients: acesulfame potassium - for effective relief from constipation, treatment of constipation, and treatment of faecal impaction defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by the physical examination of the abdomen and rectum, in adults and children 12 years and over.